Daily Newsletter

24 November 2023

Daily Newsletter

24 November 2023

Affordable Dentures & Implants opens North Columbus clinic

Part of Affordable Care's national network, the practice aims to improve patients’ access to affordable dental care.

November 24 2023

US-based Affordable Dentures & Implants has launched its new practice in North Columbus, Ohio.

Part of Affordable Care's national network, the practice aims to improve patients’ access to affordable dental care.

Services offered include extractions, partial dentures, full dentures, dental implants, and implant-secured dentures.

The practice will be led by Stephanie Harding, with Shanel Cook as the managing dentist. It operates Monday to Friday from 8am to 5pm.

Established in 1975, Affordable Dentures & Implants is said to be the largest network of dental providers in the nation focusing on tooth replacement solutions, with over 400 locations across 42 US states.

America's dental support organisation Affordable Care supports over 425 affiliated dental practices, including Affordable Dentures & Implants, in 43 states, offering non-clinical business and administrative support services.

In addition to the North Columbus facility opening, Affordable Dentures & Implants opened two new facilities in West Valley City, Utah; and Nampa, Idaho, last month.

These facilities will offer tooth replacement services, including extractions, partial dentures, full dentures, and dental implants.

Earlier this month, Affordable Care appointed Jumoke Adedoyin and Daniel Fenton as chief clinical officers for Affordable Dentures & Implants.

Dr Adedoyin will oversee new doctor development, clinic support, and engagement initiatives while Dr Fenton will continue leading clinical training, education programmes, and clinical innovation and product expansion.

Is it time for the healthcare sector to fully embrace the benefits of digitalization and AI?

Only a handful of approved therapeutic drugs are currently available for the treatment of ARF, all belonging to the solute carrier family 12 member 1 inhibitor. The clinical trial space in ARF consists of almost an equal mix of commercial as well as academic sponsors, with Iran and the US emerging as the key countries for conducting Phase III trials. While the current marketed drug space for ARF has only a handful of treatment options, currently available mid-to-late-stage pipeline drugs are likely to pave the way for a new treatment approach in the future.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close